Slide 1: Total Heart Intelligence… Wherever You Are
Total Heart Intelligence… Wherever You Are FIRST QUARTER 2026 FINANCIAL RESULTS CONFERENCE CALL MAY 13, 2026 NASDAQ: BEAT
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to the Company's future results of operations and financial position, planned products and services, business strategy and
Slide 3: Agenda
Agenda WHAT WE’LL COVER: ON THE CALL TODAY: Q1 2026 and Recent Operational Highlights HeartBeam’s Core Technology and Platform HeartBeam System: Limited Commercial Launch ROB ENO TIM CRUICKSHANK BRYAN HUMBARGER On-Demand 12-Lead ECG Patch Heart Attack Detection + AI Financials First Quarter 2026 Fin
Slide 4: Q1 2026 and Recent Operational Highlights
Q1 2026 and Recent Operational Highlights Consistent execution on near-term goals while advancing our long-term growth strategy ✓ Signed first commercial partnership with ClearCardio , a rapidly growing preventive cardiology practice. Initial ➢ Established flagship commercial sites across four targe
Slide 5: A Cardiac Intelligence Platform…Anywhere
BRINGING CARE BEYOND THE HOSPITAL A Cardiac Intelligence Platform…Anywhere. Powered by FDA-cleared ECG technology. HeartBeam is the first ever cable-free device synthesized 12-Lead ECG platform for arrhythmia assessment, delivering clinical-grade insights wherever symptoms occur. First Quarter 2026
Slide 6: One platform. Two form factors. Shared cardiac intelligence.
CORE PLATFORM One platform. PATENTED 3D SIGNAL Two form factors. COLLECTION TECHNOLOGY Shared cardiac intelligence. FORM FACTORS ON–DEMAND HEARTBEAM 12-LEAD PATCH SYSTEM CONTINUOUS CABLE-FREE 12-LEAD ECG 1-LEAD → 12-LEAD FOR AT-HOME USE ON DEMAND APPLICATIONS ENABLED ARRHYTHMIA HEART ATTACK PERSONAL
Slide 7: Clear Plan to Fuel the Next Stage of Growth
Clear Plan to Fuel the Next Stage of Growth Goals remain consistent, execution of strategy underway 1ST HALF 2026 2ND HALF 2026 2027+ Validate premium value Prove deep adoption into Scale revenue proposition anchor accounts Move to a train-the-trainer Refine HeartBeam systems Establish funnel to sup
Slide 8: Continued Execution on a Focused Commercialization Strategy
Continued Execution on a Focused Commercialization Goals established for 1st Half 2026: Status: Strategy Added Atelier Health, premier concierge Sign and onboard anchor accounts in key, targeted markets medicine practice led by physicians affiliated with Cedars-Sinai, and expanded relationship with
Slide 9: HeartBeam's On-Demand 12-Lead ECG Patch: Disrupting the Patch Market
HeartBeam’s On-Demand 12-Lead ECG Patch: Disrupting the Patch Market TODAY'S PATCH MARKET HEARTBEAM ON-DEMAND 12-LEAD PATCH Patch monitors are a $2B Development of Working Prototype of revenue market with Patch complete existing reimbursement Clinical grade 12-Lead ECG Devices are 1-3 leads, which l
Slide 10: On-Demand 12-Lead ECG Patch: Building Significant Momentum
On-Demand 12-Lead ECG Patch: Building Significant Momentum Targeting a $2 billion market with established reimbursement, the 12-Lead ECG Patch has the potential to disrupt the long-term continuous monitor and mobile cardiac telemetry (MCT) markets. Initiated Pilot Study of Novel On-Demand 12-Lead EC
Slide 11: Multiple Entry Points Into A Patient's Care Continuum
Multiple Entry Points Into A Patient’s Care Continuum • More frequent symptoms CONTINUOUS • Need to quantify arrhythmia MONITORING burden • Extended monitoring HeartBeam requested Need for deeper On-Demand 12L Patch clinical insight • Extended monitoring with 12-lead capability • Post-procedure (MI,
Slide 12: Heart Attack Detection
Heart Attack Detection Clinical-grade heart attack detection, available wherever patients are. 20M+ high-risk patients in the U.S. Problem Why We Win Status Patients can’t recognize a Two proof of concept studies ALIGN-ACS Pilot study underway heart attack at home show HeartBeam is similar to with p
Slide 13: HeartBeam Vision for Heart Attack Detection
HeartBeam Vision for Heart Attack Detection Physician augmented by deep learning algorithm with insights into STEMI and NSTEMI Patient With 24/7 Cloud-Based Cardiologist AI Interpretation of ECG ECG Data Cardiologist Cardiologist reviews: reviews: ECG • •ECG Baseline • •Baseline ECG ECG ECG Interpre
Slide 14: Upcoming Milestones
Upcoming Milestones Continued progress on commercialization and other major corporate initiatives Q1 26 Q2 26 Q3 26 Q4 26 2027- 12-LEAD FDA VALIDATE PREMIUM ESTABLISH FUNNEL FOR 2027 GOALS SCALE REVENUE CLEARANCE POSITIONING 12-LEAD LIMITED DEVELOP PROOF POINTS FOR ADOPTION LAUNCH SIGN/ONBOARD FURTH
Slide 15: Balance Sheet Strengthened with Recent Offering
Balance Sheet Strengthened with Recent Offering • Gross proceeds of $11.5 million • Closed a $10.0 million underwritten public offering of common stock on April 16, 2026 • Closed the $1.5 million overallotment in May 2026 • Round led by first commercial customer, ClearCardio; alongside our executive
Slide 16: Continued Financial Discipline Focused on Achieving Milestones
Continued Financial Discipline Focused on Achieving Milestones • Net cash used in operating activities of $3.6M in Q1 2026. YEAR-OVER-YEAR QUARTERLY CHANGE QUARTER-OVER-QUARTER CHANGE Quarter Ended March 31, Quarter Ended • 19% decrease compared to same $ in Thousands 2026i 2025 March 31, 2026i Dec.
Slide 17: Summary
Summary Executing on a $40B Cardiac Monitoring Platform Opportunity • Significantly de-risked technology • First ever FDA-cleared, cable-free synthesized 12-Lead ECG for arrhythmia assessment • Strong IP and clinical evidence • Balance sheet strengthened with April 2026 Offering • Capital-efficient
Slide 18: Q&A
Q&A Company Investor Relations Tim Cruickshank Chris Tyson CFO Executive Vice President HeartBeam, Inc. MZ North America ir@heartbeam.com Direct: 949-491-8235 BEAT@mzgroup.us www.mzgroup.us www.heartbeam.com 2118 Walsh Avenue, Suite 210 Santa Clara, CA 95050 MKT-147 v0 First Quarter 2026 Financial R